New Zealand’s government should not introduce special provisions for medical cannabis products as part of future plans to make it more accessible, University of Otago medical scientists have said.
Michelle Glass, head of the department of pharmacology and toxicology, and John Ashton from the university’s brain health research centre, say that medical cannabis products must meet the rigorous standards required for all other medicines.
In an editorial published in the New Zealand Medical Journal, they argue that “what is considered a medicine in the legal and pharmaceutical sense should not be changed in an ad hoc way to accommodate cannabis”.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.